Enalapril MaleateThird Party Manufacturing in India

Enalapril Maleate is a prodrug that belongs to the angiotensin-converting enzyme inhibitor class of medications. Following oral administration, enalapril is rapidly absorbed and hydrolyzed in the liver to its active metabolite, enalaprilat, which is a potent and competitive inhibitor of angiotensin-converting enzyme. ACE is a peptidyl dipeptidase that catalyzes the conversion of the decapeptide angiotensin I to the octapeptide angiotensin II, a powerful vasoconstrictor that also stimulates aldosterone secretion from the adrenal cortex. By inhibiting ACE, enalaprilat reduces circulating levels of angiotensin II, leading to decreased vasopressor activity, reduced peripheral vascular resistance, and lower blood pressure. The reduction in angiotensin II also decreases aldosterone secretion, resulting in reduced sodium and water retention and a modest increase in serum potassium levels. ACE is identical to kininase, an enzyme that degrades bradykinin, a potent vasodilatory peptide. ACE inhibition therefore also leads to increased bradykinin levels, which may contribute to the therapeutic effects through enhanced vasodilation. In heart failure, enalapril reduces cardiac workload by decreasing both preload and afterload, improves cardiac output, and prevents maladaptive cardiac remodeling. The comprehensive modulation of the renin-angiotensin-aldosterone system by enalaprilat produces sustained antihypertensive effects and improves outcomes in patients with heart failure and left ventricular dysfunction.

Therapeutic Uses

Enalapril Maleate is prescribed for the treatment of:

• Hypertension: For the treatment of essential and renovascular hypertension, either alone or in combination with other antihypertensive agents, particularly thiazide diuretics. It effectively lowers blood pressure in patients with mild to moderate hypertension.
• Heart Failure: For the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. It improves symptoms, increases survival, and reduces the frequency of hospitalizations in heart failure patients.
• Asymptomatic Left Ventricular Dysfunction: In clinically stable patients with left ventricular ejection fraction of 35 percent or less, enalapril decreases the rate of development of overt heart failure and reduces the incidence of hospitalization for heart failure.
• Diabetic Nephropathy: Used to slow the progression of renal disease in patients with diabetic nephropathy, particularly those with type 1 diabetes and proteinuria.

Why Manufacturers Choose Enalapril Maleate

Enalapril Maleate is one of the most widely prescribed ACE inhibitors globally and is included in the WHO Model List of Essential Medicines. It is manufactured in tablet strengths of 5mg and 10mg, covering the standard therapeutic dosing range for both hypertension and heart failure. The molecule has extensive clinical evidence supporting its efficacy and safety, with decades of post-marketing experience. For Indian manufacturers, enalapril maleate offers consistent demand across both domestic PCD franchise distribution and export markets, particularly to Europe, Africa, and Asia where ACE inhibitors are first-line antihypertensive therapy. The molecule is also available in fixed-dose combinations with hydrochlorothiazide, providing additional product line extension opportunities. Its well-established API supply chain and straightforward tablet formulation make it an accessible and commercially attractive product for WHO-GMP certified third party manufacturers.

This makes Enalapril Maleate one of the most sought-after cardiac molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export markets worldwide.